What Is Considered a High LDH Level?

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Quick answer:

Most labs set the normal LDH range at 140–280 U/L. Levels above 400 U/L generally warrant investigation, and readings above 1,000 U/L often point to serious conditions such as tissue death, certain cancers, or severe red blood cell destruction. Because LDH exists in five isoenzyme forms across multiple organs, context from related biomarkers matters as much as the number itself.

Read more →

Understand what your cancer tumor marker testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

What LDH level is considered high?

Most labs set normal LDH at 140-280 U/L. Above 400 U/L warrants investigation, and above 1,000 U/L often signals a serious condition.

LDH (U/L)BandWhat it usually means
Below 140LowUncommon, and usually less concerning than a high result
140-280NormalMost labs' range; some extend the upper limit to 300
280-400Mildly highRead alongside symptoms, your own trend, and related markers
Above 400HighGenerally warrants investigation, especially with symptoms
Above 1,000SevereOften tissue death, certain cancers, or severe hemolysis (red blood cell destruction)

Against a 280 U/L cutoff, an LDH of 260 is normal and 300 is mildly high, while labs that extend to 300 read both as normal.

Lab reference ranges represent the middle 95% of values from apparently healthy people. Normal marks the absence of a flagged problem, not necessarily an optimal level.

What's considered "high" also depends on several factors. Age matters: children and teenagers often have higher baseline LDH due to rapid growth and development. Pregnancy can also elevate levels. Some people naturally run higher or lower within the normal range.

Your individual pattern provides more insight than population averages. If your LDH typically runs around 200 U/L and suddenly jumps to 350 U/L, that's more significant than someone whose baseline is consistently around 320 U/L. Context and related biomarkers help determine urgency.

Lowering a high LDH means treating its source: rest after hard exercise, a review of medications that damage tissue, or care for the underlying condition.

What LDH actually measures

Lactate dehydrogenase is an enzyme that helps convert glucose into energy inside your cells. Think of it as part of your cellular power plant. Every tissue in your body contains LDH, but some areas have much higher concentrations.

Your heart, liver, kidneys, muscles, brain, and blood cells are particularly rich in LDH. When these tissues experience damage, stress, or rapid turnover, cells break open and dump their LDH contents into your bloodstream. Your blood test measures this spillover.

LDH isn't specific to one organ or condition. It's more like a smoke detector that alerts you to cellular damage somewhere in your body, but doesn't tell you exactly where the fire is burning. This makes LDH useful as a screening tool but requires additional testing to pinpoint the source.

The enzyme exists in five different forms (isoenzymes), each more common in specific tissues. Advanced testing can identify which isoenzyme is elevated, providing clues about whether the damage involves your heart, liver, muscles, or other areas.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Does high LDH mean cancer?

Not by itself, because LDH rises whenever cells break open, and cancer is one possible cause among several. A high result tells you damage is happening, not where it comes from.

Certain cancers, particularly blood cancers like lymphoma and leukemia, can dramatically increase LDH. Solid tumors with rapid growth or cell death also elevate levels. This makes LDH useful for tracking a known cancer, not for finding one on its own.

Many conditions besides cancer also raise LDH when they damage tissue. Heart attacks cause LDH to rise as heart muscle cells die, though other markers like troponin are more specific and faster. Liver damage from medications, alcohol, or disease releases LDH along with liver enzymes like ALT and AST.

Muscle damage from intense exercise, injury, or muscle diseases can spike LDH levels. Marathon runners or people who've had significant muscle trauma often show temporary elevations. Blood disorders like hemolytic anemia destroy red blood cells, releasing their high LDH content.

Infections, especially those causing significant tissue damage or inflammation, can raise LDH. Pneumonia, meningitis, and severe bacterial infections often show elevated levels alongside other inflammatory markers like C-reactive protein.

What low LDH levels can mean

Low LDH levels are less common and usually less concerning than high levels. Your body constantly produces LDH as part of normal cellular metabolism, so extremely low levels are rare unless something is interfering with cellular function.

Certain genetic conditions can affect LDH production, though these are uncommon. Some medications might temporarily lower levels. Severe nutritional deficiencies that impair cellular metabolism could theoretically reduce LDH, though other symptoms would be apparent first.

More often, "low" LDH simply reflects good cellular health with minimal ongoing damage or turnover. If you're healthy and your LDH sits at the lower end of the normal range, this generally indicates your tissues are functioning well without significant stress.

Lab error or sample handling issues occasionally produce falsely low results. If your LDH seems unusually low compared to previous tests, discussing a retest with your care team makes sense, especially if accompanied by unexplained symptoms.

How LDH is tested

LDH testing requires a simple blood draw, typically from a vein in your arm. No fasting is required, and you can take medications normally unless specifically instructed otherwise. The blood sample goes to a lab where automated analyzers measure enzyme activity.

Sample handling matters for accurate results. LDH is released when blood cells break down, so rough handling or delayed processing can artificially elevate levels. Hemolysis (breakdown of red blood cells) in the sample can significantly increase measured LDH even if your actual blood level is normal.

Results are usually available within 24-48 hours. If your care team suspects muscle damage, heart problems, or certain cancers, they might order LDH along with other specific markers to provide better context for interpretation.

Retesting frequency depends on your situation. For monitoring known conditions like cancer treatment response, testing might occur every few weeks. For general health screening, annual testing is often sufficient unless symptoms develop or other biomarkers suggest cellular damage.

What can change LDH

Physical factors significantly influence LDH levels. Intense exercise, especially activities involving muscle damage like weight lifting or long-distance running, can temporarily elevate LDH for 24-72 hours. Heat stroke or severe dehydration can also increase levels.

Medications affect LDH in various ways. Some chemotherapy drugs, antibiotics, and pain medications can cause tissue damage that raises LDH. Statins occasionally cause muscle damage that increases levels, though this is uncommon at standard doses.

Medical procedures involving tissue trauma can temporarily spike LDH. Surgery, biopsies, or even aggressive massage can release cellular contents. Blood transfusions might temporarily alter levels if the donated blood has different LDH concentrations.

Underlying health conditions create chronic LDH elevation. Liver disease, kidney problems, muscle disorders, blood diseases, and active cancers can keep levels consistently high. Treating the underlying condition typically normalizes LDH over time.

Test 100+ biomarkers

One blood draw. A full picture of your health, explained in plain language.

Book your test

LDH interpretation improves dramatically when viewed alongside related markers. Liver enzymes (ALT, AST, alkaline phosphatase) help determine if elevation comes from liver damage. If LDH and liver enzymes rise together, liver problems are likely.

Muscle-specific markers like creatine kinase (CK) clarify whether muscle damage is contributing to LDH elevation. High LDH with normal CK suggests non-muscle sources like liver, heart, or blood cells.

Inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) provide context about whether LDH elevation relates to infection, inflammation, or tissue damage. Complete blood counts can reveal blood disorders that might explain high LDH.

Heart-specific markers like troponin are much more sensitive for heart damage than LDH. If you have chest pain with high LDH but normal troponin, heart attack is less likely. Kidney function markers help determine if kidney damage is contributing to LDH changes.

Understanding your LDH results

LDH works as an early warning for cell damage across many organs, but it can't name the source. In cancer care, rising or falling levels track tumor activity and treatment response. For everyone else, a trend says more than one reading, and gradually rising levels can flag a developing problem. Superpower's panels measure liver enzymes, inflammatory markers, and other signs of cell health that help explain a high LDH result.

Frequently Asked Questions

References

  1. Ali F, Ullah A, Amjad W, Kochar T, Annie FH, Farooq A (2018). A Case of Recurrent Thrombotic Microangiopathy Caused by Hypertensive Urgency. *Cureus*, *10*(8), e3235. https://doi.org/10.7759/cureus.3235
  2. Farhana A, Lappin SL (2023). *Biochemistry, lactate dehydrogenase*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557536/
  3. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S (2015). Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. *Acta oncologica (Stockholm, Sweden)*, *54*(7), 961-70. https://doi.org/10.3109/0284186X.2015.1043026
  4. Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Lonati V, Ghilardi M, Barni S (2015). Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. *Medical oncology (Northwood, London, England)*, *32*(2), 456. https://doi.org/10.1007/s12032-014-0456-z
  5. Lippi G, Salvagno GL, Montagnana M, Brocco G, Guidi GC (2006). Influence of hemolysis on routine clinical chemistry testing. *Clinical chemistry and laboratory medicine*, *44*(3), 311-6. https://doi.org/10.1515/CCLM.2006.054
  6. Koukourakis MI, Giatromanolaki A, Sivridis E, Tumour and Angiogenesis Research Group (2003). Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*, *24*(4), 199-202. https://doi.org/10.1159/000074430
  7. Åsberg A, Mikkelsen G (2024). A bivariate reference interval for TSH and free thyroxine. *Scandinavian journal of clinical and laboratory investigation*, *84*(7-8), 521-526. https://doi.org/10.1080/00365513.2024.2437613
  8. Guo W, Zhou Q, Jia Y, Xu J (2019). Age- and Sex-Specific Reference Intervals for Myocardial Enzyme Activity in Healthy Chinese Han Population Aged 1∼<18 years. *BioMed research international*, *2019*, 2018598. https://doi.org/10.1155/2019/2018598
  9. Nalla SD, Chopra S, Rama S, Lambroussis CG (2025). Intravascular Hemolysis and Acute Kidney Injury Following an Emergent Cesarean Delivery: A Case Report. *Cureus*, *17*(8), e90331. https://doi.org/10.7759/cureus.90331
  10. Trapé J, Montesinos J, Franquesa J, Sala M, Fígols C, Miguel A, Domenech M (2011). Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma. *Clinical chemistry and laboratory medicine*, *50*(5), 927-9. https://doi.org/10.1515/CCLM.2012.799
  11. Cita KC, Brureau L, Lemonne N, Billaud M, Connes P, Ferdinand S, Tressières B, Tarer V, Etienne-Julan M, Blanchet P, Elion J, Romana M (2016). Men with Sickle Cell Anemia and Priapism Exhibit Increased Hemolytic Rate, Decreased Red Blood Cell Deformability and Increased Red Blood Cell Aggregate Strength. *PloS one*, *11*(5), e0154866. https://doi.org/10.1371/journal.pone.0154866
  12. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, ESC Scientific Document Group (2019). Fourth universal definition of myocardial infarction (2018). *European heart journal*, *40*(3), 237-269. https://doi.org/10.1093/eurheartj/ehy462
  13. Hu J, Zhou S, Ryu S, Adams K, Gao Z (2023). Effects of Long-Term Endurance Exercise on Cardiac Morphology, Function, and Injury Indicators among Amateur Marathon Runners. *International journal of environmental research and public health*, *20*(3). https://doi.org/10.3390/ijerph20032600
  14. Wu W, Miao L, Zhao L, Zhu Y, Mao J, Cai Z, Ji Y, Wang L, Wang Y, Jia T (2024). Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase/albumin ratio in patients with diffuse large B-cell lymphoma. *Hematology (Amsterdam, Netherlands)*, *29*(1), 2293514. https://doi.org/10.1080/16078454.2023.2293514
  15. Mu T, Wang X, Lu Z, Tong J (2023). Implications of LDH in patients with coronavirus disease 2019 pneumonia. *Frontiers in cellular and infection microbiology*, *13*, 1180187. https://doi.org/10.3389/fcimb.2023.1180187
  16. Nussinovitch M, Finkelstein Y, Elishkevitz KP, Volovitz B, Harel D, Klinger G, Razon Y, Nussinovitch U, Nussinovitch N (2009). Cerebrospinal fluid lactate dehydrogenase isoenzymes in children with bacterial and aseptic meningitis. *Translational research : the journal of laboratory and clinical medicine*, *154*(4), 214-8. https://doi.org/10.1016/j.trsl.2009.06.011
  17. Smajić J, Halilović FI, Mujkić L, Sijerčić S, Smajić E, Delibegović S (2026). The clinical relevance of the COVID-19-associated hyperinflammatory syndrome score in the ICU: A single-center retrospective observational study. *Science progress*, *109*(1), 368504261421431. https://doi.org/10.1177/00368504261421431
  18. Monroe GR, van Eerde AM, Tessadori F, Duran KJ, Savelberg SMC, van Alfen JC, Terhal PA, van der Crabben SN, Lichtenbelt KD, Fuchs SA, Gerrits J, van Roosmalen MJ, van Gassen KL, van Aalderen M, Koot BG, Oostendorp M, Duran M, Visser G, de Koning TJ, ... Jans JJ (2019). Identification of human D lactate dehydrogenase deficiency. *Nature communications*, *10*(1), 1477. https://doi.org/10.1038/s41467-019-09458-6
  19. Kaviani M, Abassi A, Chilibeck PD (2019). Creatine monohydrate supplementation during eight weeks of progressive resistance training increases strength in as little as two weeks without reducing markers of muscle damage. *The Journal of sports medicine and physical fitness*, *59*(4), 608-612. https://doi.org/10.23736/S0022-4707.18.08406-2
  20. Huang Y, Long L, Huang Q, Wang Q, Jin K, Ju T, Dai L, Xu H, Wang W, Zhou Q (2024). [Observation on the efficacy of continuous veno-venous hemodia-filtration combined with hemoperfusion HA380 in the treatment of 15 cases of heat stroke with multiple organ dysfunction syndrome]. *Zhonghua wei zhong bing ji jiu yi xue*, *36*(5), 532-537. https://doi.org/10.3760/cma.j.cn121430-20230728-00561
  21. Jin F, Yang M, Chen Y, Jiang L, Liu L (2020). Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report. *Medicine*, *99*(45), e22632. https://doi.org/10.1097/MD.0000000000022632
  22. Ansari Z, Findakly D, Wang J (2020). A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer. *Cureus*, *12*(5), e8257. https://doi.org/10.7759/cureus.8257
  23. Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD (2017). Optimizing Cholesterol Treatment in Patients With Muscle Complaints. *Journal of the American College of Cardiology*, *70*(10), 1290-1301. https://doi.org/10.1016/j.jacc.2017.07.752
  24. Sándor Z, Katics D, Varga, Á., Kalmár Nagy K, Szakály P (2024). Interpretation of LDH Values after Kidney Transplantation. *Journal of clinical medicine*, *13*(2). https://doi.org/10.3390/jcm13020485
  25. Takagi Y, Yasuhara T, Gomi K (2001). [Creatine kinase and its isozymes]. *Rinsho byori. The Japanese journal of clinical pathology*, *Suppl 116*, 52-61. https://pubmed.ncbi.nlm.nih.gov/11797380/
  26. Alende-Castro V, Alonso-Sampedro M, Fernández-Merino C, Sánchez-Castro J, Sopeña B, Gude F, Gonzalez-Quintela A (2021). C-Reactive Protein versus Erythrocyte Sedimentation Rate: Implications Among Patients with No Known Inflammatory Conditions. *Journal of the American Board of Family Medicine : JABFM*, *34*(5), 974-983. https://doi.org/10.3122/jabfm.2021.05.210072

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Biological age 32 — a Superpower member portraitA health system built around you — test, understand, optimize100+ biomarkers across 2 blood drawsWhat to expect with Superpower — week 1 to month 3Trusted by 64,000+ customers — member reviewsBetter than the status quo — Superpower vs the old way60% of members found something a doctor missed — member survey
Daniel OSuperpower memberDavid LSuperpower memberRachel DSuperpower memberCamelia VSuperpower member

4.6 · 64,000+ members

Superpower health membership

Find early signs of 1,000+ conditions from a single blood draw - then act on what you find.

$199

/year*

100+ biomarkers from a single blood draw

Personalized plan that turns results into action

Superpower AI and on-demand care team

Results in 10 days or less

At-home or 2,000+ labs nationwide**

Yearly membership$0.55 / dayHSA/FSA eligible

*Pricing may vary for members in New York and New Jersey

**At-home labs for an additional cost

What we test

TestosteroneFree T4Vitamin DApoBHbA1cThyroid (TSH)hs-CRPFerritinCortisolFasting insulin

60%

found something a doctor missed

93%

rated it more useful than their checkup

77%

found something new in their results

Superpower member survey, 90 days post action plan (n=143).

How does the Superpower membership work?

We test 100+ biomarkers from a single blood draw each year. Your baseline test paints a comprehensive picture of your health, and your dashboard shows what’s working, what needs attention, and what to do next. Superpower AI and your care team help you take action across lifestyle, supplements, and treatments.

Can I cancel anytime?

Yes. You can cancel anytime, no fees. Your membership stays active through the end of your paid year.

How often should I test?

Your membership includes two blood tests per year: one to establish your baseline, and one to see whether your plan improved biomarkers that were out of range or not yet optimized. You can add other diagnostics anytime through the app or with help from your care team.

When will I get my results?

Book your draw at any of 2,000+ partner labs or at-home. Results are typically ready in about a week and land in the Superpower app.